Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Gains from Investment Securities (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Gains from Investment Securities for 4 consecutive years, with $29.6 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 483.87% to $29.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $20.6 million for FY2025, 8.39% up from the prior year.
  • Gains from Investment Securities hit $29.6 million in Q4 2025 for NewAmsterdam Pharma, up from $4.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $29.6 million in Q4 2025 to a low of -$7.7 million in Q4 2024.
  • Historically, Gains from Investment Securities has averaged $12.3 million across 4 years, with a median of $14.3 million in 2022.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 1161.31% in 2024 and later tumbled 76.73% in 2025.
  • Year by year, Gains from Investment Securities stood at $11.4 million in 2022, then plummeted by 85.93% to $1.6 million in 2023, then crashed by 581.94% to -$7.7 million in 2024, then soared by 483.87% to $29.6 million in 2025.
  • Business Quant data shows Gains from Investment Securities for NAMS at $29.6 million in Q4 2025, $4.7 million in Q3 2025, and $22.2 million in Q2 2025.